An Open-label Pilot Study of the Effect of Second-line Treatment With Herceptin Monotherapy on Time to Disease Progression in Patients With Metastatic Urothelial Cancer and HER2 Overexpression
Phase of Trial: Phase II
Latest Information Update: 07 Oct 2014
At a glance
- Drugs Trastuzumab (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- Sponsors Roche
- 19 Dec 2013 New source identified and integrated, ClinicalTrials.gov record.
- 23 Feb 2010 Status changed from recruiting to completed as reported by Roche record
- 23 Jul 2009 Status changed from active, no longer recruiting to recruiting as reported by Roche record.